Adalimumab Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Adalimumab Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Global Adalimumab Drugs Market is projected to register a CAGR of 5.1% during the forecast period (2022-2027).

COVID-19 has put infectious-disease antibodies back in the spotlight. As per an article titled “Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients” published in March 2022, patients with Immunomodulatory drugs (IMiDs) treated with infliximab and adalimumab have attenuated serological responses to SARS-CoV-2 infection with lower seroprevalence and antibody reactivity when compared to vedolizumab-treated patients. Therefore, the drug is expected to have a significant impact on COVID patients during the pandemic and affect the growth of the market respectively. As per another article titled “COVID antibody drugs have saved lives — so why aren’t they more popular?” published in June 2022, Adalimumab, which is considered the top-selling drug in the pandemic, soothes rheumatoid arthritis and other autoimmune conditions by mopping up the inflammatory protein TNF-α. Pembrolizumab, on track to overtake adalimumab’s sales, binds to a protein on the immune system’s T cells to unleash the body’s defenses against cancers. This is also expected to have a significant impact on market growth. In 2021, the Food and Drug Administration (FDA) approved its 100th monoclonal antibody, and these drugs collectively reap around USD 150 billion in sales worldwide every year.

Biopharmaceutical medicines have transformed the way that a wide range of disorders are treated, and they are being utilized more often in almost all areas of medicine. Due to the enormous demand for these medications, the market for biopharmaceuticals has grown significantly more quickly than the overall pharmaceutical market in recent years and is thought to have a significant amount of potential for further dynamic growth. Single-use systems represent the future in biopharmaceutical processing of therapeutic drugs with significant advantages over traditional reusable stainless-steel systems and partly disposable systems. As per the Global RA Network-2022, arthritis affects more than 350 million people and became a leading cause of disability which trigger market growth. The prevalence of arthritis, growing acceptance of biopharmaceuticals, and the presence of well-defined regulatory guidelines in developed economies are among the key trends expected to trigger market growth.

Increasing launches of novel biosimilar and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, in May 2022, Biocon Biologics Ltd. and Viatris Inc. announced that Abevmy is available in Canada. Abevmy, co-developed by Biocon Biologics and Viatris, is biosimilar to Roche’s Avastin and has been approved by Health Canada across four oncology indications. Similarly, in February 2022, Dr. Reddy's Laboratories launches a generic drug in the United States market. Additionally, in January 2022, Biocon reported strong growth in its biosimilars business and the launch of the first interchangeable biosimilar glargine in the US will drive further growth in this segment. Similarly, ABP 501, a novel Adalimumab biosimilar by Amgen, is awaiting approval by 2020. Recently approved biologics such as Hyrimoz (adalimumab-adaz) by Novartis and ABRILADA (adalimumab-AFB) by Pfizer is poised to have strong market penetration due to the presence of a favorable reimbursement scenario.

Growing patient awareness regarding arthritis disorders and the influx of new biopharmaceuticals in the global arena are projected to increase the adoption of adalimumab drugs. For instance, as per an article titled “The Prevalence and Statistics of Arthritis” published in February 2022, the prevalence of arthritis in the United States has increased, and it will continue to climb as the baby boomer generation ages. More than 22% of American adults (over 52.5 million people) have arthritis or another rheumatic condition diagnosed by doctors. By 2030, the number of people with arthritis (adults 18 years and older) is expected to rise to 67 million. Similarly, according to the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population, data published in October 2021, about 1 in 4 US adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis. Arthritis prevalence increases with age. Therefore, the aging population can also be a driving factor for the market. According to World Health Organization (WHO) key facts updated in October 2021, By 2020, the number of people aged 60 years and older will outnumber children younger than 5 years and between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. Thus the increasing age and the increasing prevalence and awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth and accelerate the market.

However, side effects associated with this drug such as vomiting, nausea, internal bleeding, anaphylaxis, and respiratory tract infections may restrain the growth of the market.

Key Market TrendsRheumatoid Arthritis Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

Rheumatoid arthritis is expected to dominate the global adalimumab drugs market through the forecast period. This can be attributed to the rising prevalence of rheumatoid arthritis which causes different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and the inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

According to an article titled “The Prevalence and Statistics of Arthritis” published in February 2022, the incidence of rheumatoid arthritis is 2 to 3 times higher in women than men. In both men and women, the onset of rheumatoid arthritis is highest among people in their 60s. Another article titled “Epidemiology of risk factors for, and possible causes of rheumatoid arthritis” published in 2022, states that rheumatoid arthritis (RA) is estimated to affect approximately 0.24% to 1% of the population and to be twice as common in women compared with men. A range of poor long-term outcomes can potentially occur, but these have been reduced to some degree with the use of more aggressive treatment strategies and more effective drug therapies. Thus, the rheumatoid arthritis segment is witnessing a shift toward combination therapies that provide enhanced results to patients. This is expected to drive segmental growth and accelerated market growth.

As per an article titled “How to Afford Biologics for RA” published in December 2021, types of biologics your doctor may recommend for rheumatoid arthritis includes tumor necrosis factor (TNF) inhibitors like adalimumab (Humira), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), and infliximab (Remicade). Thus, the cost of the drugs to be consumed can be made of low cost by the private health insurance plans covering biologics for rheumatoid arthritis. This is expected to accelerate segmental growth.

Higher availability, positive results, and low price of a biosimilar for the target disease are supplementing the growth of the segment. The introduction of new biosimilars such as Hadlima and Adaly in the treatment of rheumatoid arthritis is poised to create a significant shift in prescription patterns.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of RA, and high public and private healthcare spending are stimulating the growth of the region. As per the World Health Organization, an estimated 54.4 million adults in the United States suffer from rheumatoid arthritis. Moreover, easy access to quality healthcare, favorable reimbursement policies, a strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America. For instance, in November 2021, Amgen said that its seeking interchangeability status for its low-concentration adalimumab biosimilar (Amjevita). Amjevita was approved by the FDA in September 2016 and is expected to be the first adalimumab biosimilar to launch in the United States in January 2023. In January 2022, Samsung Bioepis and Organon announced that they are seeking interchangeability for a high-concentration, citrate-free version of their adalimumab biosimilar (Hadlima), which was approved as a low-concentration formulation in July 2019 and is expected to launch on the US market in June 2023. Additionally, in October 2021, The United States Food and Drug Administration approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to, and interchangeable with, its reference product Humira (adalimumab) for Cyltezo’s approved uses.

Asia Pacific is likely to post the fastest market throughout the forecast horizon. Growing adoption of the urban lifestyle is leading to expanding base of patients in the region. This, coupled with increasing healthcare spending, is expected to propel the market in the APAC region. Favorable regulatory policies for biosimilars are estimated to boost demand for adalimumab over the forecast period.

Price-sensitive regions such as Latin America and MEA have higher acceptance of generic drugs as compared to innovator biologics due to lower prices. Increasing demand for biosimilars for disease reversal is poised to augment the regional markets during the forecast period.

Competitive Landscape

Manufacturers offering biosimilars dominate the global adalimumab drugs market. Companies are focusing on building novel chemical entities and innovative molecules to consolidate their foothold. Some of the prominent market participants are AbbVie Inc; Boehringer Ingelheim GmbH, Novartis AG; Pfizer Inc., F. Hoffmann-La Roche Ltd., Cadila Healthcare Ltd, Hetero Healthcare Limited and Amgen, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.